ObjectiveTo evaluate the combination of pembrolizumab. cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer. MethodsPatients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle. Pembrolizumab was administered on day 1 of cycles 3-6 and as maintenance monotherapy in cycles 7-34. https://chefesquipmenters.shop/product-category/gravy-boat/